LUNDBECK A Aktie

 

Appointments support Harmony's next phase of growth and long‑term value creationPLYMOUTH MEETING, Pa.--(BUSINESS WIRE)--Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced the appointment of Peter Anastasiou as Chief Operating Officer and updates to its Board of Directors, including the appointment of Troy Ignelzi as a director and the nomination of Geno J. Germano as a director for election at Harmony's 2026 Annual Meeting of Shareholders. Mr. Anastasiou previously served on Harmony Biosciences' Board of Directors, where he contributed strategic insight across the business during a period of continued growth and operational evolution. He brings more than three decades of experience building and leading biotechnology organizations. Most recently, Mr. Anastasiou served as Chief Executive Officer of Capsida Biotherapeutics and previously held multiple leadership roles at Lundbeck, including President of U.S. and Canadian operations and U.S. Chief Commercial Officer for its psychiatry and ...

H. Lundbeck A/S (Lundbeck) announced today that the report by the Board of Directors was adopted and the annual report was approved at the annual general meeting. The proposal to distribute a dividend of 36% of the net profit and 30% of net profit adjusted for the impairment loss of the planned divestment of a non-core production site in Italy for the accounting year 2025, corresponding to DKK 1.15 per share, or a total dividend of DKK 1,145 million, was adopted. The Remuneration Report for 2025 was approved in the advisory vote. Dorothea Wenzel, Lene Skole-Sørensen, Lars Erik...

Phase 1b data on Lu AF28996, an investigational treatment for people with advanced Parkinson's disease, to be presented at the 2026 AD/PD™ Conference Data evaluated safety, tolerability, pharmacokinetics and early clinical signals of Lu AF28996 Five accepted presentations reflect......

H. Lundbeck A/S will focus its capital investments on the US and China rather than Europe as the region faces growing pressure to incentivize innovation, according to the Danish drugmaker's chief executive officer....

VALBY, Denmark, March 10, 2026 /PRNewswire/ -- H. Lundbeck A/S (Lundbeck) today announced the appointment of Markus Kede as Senior Vice President, Chief AI Officer. He will join the Executive Leadership Team and report to President and CEO, Charl van Zyl. The appointment marks an......

· MASCOT is a first-of-its-kind, Phase 3 trial supporting the development of amlenetug, an investigational therapy for people living with multiple system atrophy (MSA), a rare and fatal neurodegenerative disorder[1] · Amlenetug is a novel monoclonal antibody that demonstrated promising results in a Phase 2 trial, suggesting potential to slow disease progression in MSA · Early completion of randomization underscores the significant unmet need in MSA, strong collaboration with patient and investigator communities, and Lundbeck's robust research and development capabilities · Headline...

Weltweit wichtigster Preis für Hirnforschung wird für bahnbrechende Entdeckungen über Tastsinn und Schmerzempfinden des Menschen verliehen...

+--+-----------------+------------+---------+ |1.|Details of the | | |person | | |discharging | | |managerial | | |responsibilities | | |/ person closely | | |associated | +--+-----------------+------------+---------+ |a)|Name | Lars Bang | +--+-----------------+------------+---------+ |2.|Reason for the | | |notification...

NOTICE OF ANNUAL GENERAL MEETING Notice is hereby given of the annual general meeting of H. Lundbeck A/S to be held on: WEDNESDAY, 18 MARCH 2026 AT 10:00 AM CET The annual general meeting will be held at the offices of the Company at: H. Lundbeck A/S, Ottiliavej 9, DK-2500 Valby Agenda In accordance with Article 8.1 of the Articles of Association, the agenda of the meeting is as follows: 1. Report of the Board of Directors on the Company's activities during the past year. 2. Presentation and adoption of the annual report. 3. Resolution on the appropriation of...

· The intravenous (IV) part of the phase IIb dose-finding PROCEED trial of bocunebart (Lu AG09222) met its primary endpoint in migraine prevention, demonstrating a statistically significant difference to placebo in the change from baseline in the number of monthly migraine days (MMDs) over weeks 1 to 12 in a population that experienced past treatment failures. · The results demonstrate the potential of bocunebart in severe migraine. · Additional analyses will be done to better understand the dose–response relationship across the investigated doses. · Based on this positive outcome,...

H. Lundbeck A/S (Lundbeck) hereby publishes and reports transactions made by executives and persons closely associated with them with shares and linked securities in Lundbeck. +--+-----------------+------------+---------+ |1.|Details of the | | |person | | |discharging | | |managerial | | |responsibilities | | |/ person closely | | |associated | +--+-----------------+------------+--------...

H. Lundbeck A/S (Lundbeck) hereby publishes and reports transactions made by executives and persons closely associated with them with shares and linked securities in Lundbeck. +--+-----------------+----------+---------+ |1.|Details of the | | |person | | |discharging | | |managerial | | |responsibilities | | |/ person closely | | |associated | +--+-----------------+----------+---------+ |a)|Name...

Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...

Annual report 2025 in XHTML format submitted to the Danish Financial Supervisory Authority (The Officially Appointed Mechanisms)...

Key highlights Lundbeck's total revenue grew by +13% CER[1] (+12% DKK) to DKK 24,630 million in 2025, driven primarily by strong performance in the U.S. and Europe. · United States: DKK 13,287 million (+21% CER; +17% DKK) · Europe: DKK 5,819 million (+13% CER; +13% DKK) · International Operations: DKK 4,858 million (-3% CER; -7% DKK) The revenue of Lundbeck's strategic brands increased by +19% CER (+15% DKK), reaching DKK 19,011 million, representing 77% of total revenue. · Rexulti[®]: DKK 6,205 million (+23% CER; +19% DKK) · Brintellix[®]/Trintellix[®]: DKK 4,554...

New six-month results from the Vyepti® (eptinezumab) 12-month, real-world INFUSE study presented at the 2026 Headache Cooperative of the Pacific (HCOP) Annual Conference, Ojai, California1 The INFUSE study includes adults with migraine who had failed at least one preventive......

H. Lundbeck A/S (Lundbeck) hereby publishes and reports transactions made by executives and persons closely associated with them with shares and linked securities in Lundbeck. +--+-----------------+----------+---------+ |1.|Details of the | | |person | | |discharging | | |managerial | | |responsibilities | | |/ person closely | | |associated | +--+-----------------+----------+---------+ |a)|Name...

New long-term data presented at AES 2025 indicate reductions in seizure frequency are maintained for up to two years after treatment initiation with bexicaserin in patients with Developmental and Epileptic Encephalopathies (DEEs)1 DEEs are a group of devastating, rare epilepsies......

New data to be presented at the 2025 AES Annual Meeting indicate sustained reductions in seizure frequency as early as two weeks after treatment initiation with bexicaserin1 Bexicaserin is an investigational compound in development for the treatment of seizures associated with a broad......

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY (IN WHOLE OR IN PART) IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION. H. Lundbeck A/S (“Lundbeck”) No offer for Avadel Pharmaceuticals plc (“Avadel”) Further to the announcement under Rule 2.7 of the Irish Takeover Rules by Avadel and Alkermes plc on November 19, 2025, Lundbeck confirms that it does not intend to make an offer for Avadel. Accordingly, Lundbeck will be bound by the restrictions set out in Rule 2.8 of the Irish Takeover Rules....